Roche acquisition of Spark Therapeutics for $4.5bn in February 2019 is a day to remember for many biotech investors. This was one of the blockbuster deals of 2019 that contributed … Continue reading Case study – what we can learn from Spark Therapeutics acquired at 122% premium by Roche in 2019